Sep 18, 2024
Charles Joynson, WaveData MD, has conducted some indepth analysis to try to identify early warning signs of generic shortages. Here’s the first instalment. Over the last few years, WaveData has repeatedly analysed shortages and concessions, trying to find links...
Jul 10, 2024
Twice before WaveData to have looked into this subject only to find there is no link between product value and the delay in the introduction of Category M. However, time moves on, so we thought we’d repeat the analysis, partly because of a recent client request, and...
Jun 18, 2024
Prompted by a Client’s questions about Category M and the formula that goes behind it to drive Pharmacy profitability, we asked Charles Joynson, WaveData MD, to have a closer look at Category M to see if he can make any sense of it. Initially that we assumed that the...
Feb 8, 2024
WaveData conducted a comparison of the average market prices given to accounts (pharmacies and dispensing doctors) by respiratory product manufacturers. The average discounts given over a 10 year period are very consistent at 9%, which probably reflects the underlying...
Nov 9, 2023
It would seem sensible to assume that profitable products are less likely to suffer shortages, concessions and price spikes than products where profit is hard to come by. Charles Joynson, WaveData MD, compared the reimbursement price and the average market price for...
Oct 10, 2023
Charles Joynson, WaveData MD, drilled into this to see where the increase is coming from, demonstrating that it’s a mixture of parallel import and generics which are driving the rise. – Parallel imports have risen from £22.73 in Sept 2013 to 26.24 in August...
